VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: November 30, 2024

VALNEVA - Declaration of shares and voting rights: November 30, 2024

VALNEVA

Declaration of shares and voting rights

November 30, 2024

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: December 5, 2024

Number of shares

composing the share capital of Valneva 		Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 162,494,003



 ordinary shares with a par value of €0.15 each 		178,371,727





Transfer into bearer form of 1,000 shares with double voting rights



 



Double voting rights granted on 7,052 ordinary shares



  		November 26, 2024



 



Between November 1 & 30, 2024 		178,247,405

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
05/12/2024

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Bruno Bulic
  • Bruno Bulic
VLS VALNEVA SE

Valneva pushing Ixchiq in Asia

Valneva announced an exclusive license agreement with India-based Serum Institute of India (SII), for the supply of the Chikungunya vaccine Ixchiq in Asia, a partnering falling under the scope of the Coalition for Epidemic Preparedness Innovations (CEPI) for low-and-middle-income countries (LMICs)

9h / 54m 9h / 54m 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccin...

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India Saint-Herblain (France), Pune, (India), December 19, 2024 – (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s largest manufacturer of vaccines by number of doses, today announced an exclusive license agreement for Valneva’s single-shot chikungunya vaccine that enables supply of the vaccine in Asia. The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the fram...

10h / 40m 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva accroît l’accessibilité de son vaccin contre le chikungunya en...

Valneva accroît l’accessibilité de son vaccin contre le chikungunya en Asie grâce à une collaboration avec le Serum Institute of India Saint-Herblain (France), Pune, (Inde), le 19 décembre 2024 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, et le Serum Institute of India (SII), plus grand fabricant de vaccins au monde en nombre de doses, ont annoncé la signature d’un accord de licence exclusif pour le vaccin à dose unique de Valneva contre le chikungunya, permettant la fourniture du vaccin en Asie. Cette collaboration destinée à accroître l’accessibilité du...

10h / 40m 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA - Declaration of shares and voting rights: November 30, 2024

VALNEVA - Declaration of shares and voting rights: November 30, 2024 VALNEVA Declaration of shares and voting rights November 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: December 5, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change ...

December 5, 2024 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Reports Positive Three-Year Antibody Persistence Data for its ...

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Antibody levels remained high at 96% seroresponse in line with the two-year persistence data This long-lasting antibody persistence was comparable in older (65+) and younger adults Saint-Herblain (France), December 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectat...

December 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch